Stockscreener 앱 받기
10.99
3.19%
0.34
전일 마감가:
$10.65
열려 있는:
$10.59
하루 거래량:
1.24M
Relative Volume:
0.57
시가총액:
$1.41B
수익:
-
순이익/손실:
$-29.07M
주가수익비율:
-37.90
EPS:
-0.29
순현금흐름:
$-31.85M
1주 성능:
-3.34%
1개월 성능:
+3.19%
6개월 성능:
+77.83%
1년 성능:
+302.56%
1일 변동 폭
$10.46
$11.21
1주일 범위
$10.46
$11.67
52주 변동 폭
$2.36
$12.30
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
TRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
10.99 | 1.37B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Leerink Partnrs Has Bullish Outlook for TRVI FY2025 Earnings - MarketBeat
B. Riley Increases Earnings Estimates for Trevi Therapeutics - MarketBeat
Leerink Partners Maintains Trevi Therapeutics (TRVI) Outperform Recommendation - Nasdaq
TRVI's Price Target Raised by Leerink Partners to $16.00, Mainta - GuruFocus
What is B. Riley's Forecast for TRVI Q1 Earnings? - MarketBeat
Can Trevi Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Fed Impact & Stock Portfolio Risk Management - newser.com
Analyzing drawdowns of Trevi Therapeutics Inc. with statistical toolsBreakout Watch & Verified High Yield Trade Plans - newser.com
How resilient is Trevi Therapeutics Inc. stock in market downturns2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Leerink Partners raises Trevi Therapeutics stock price target to $16 on Haduvio outlook By Investing.com - Investing.com South Africa
Is now a turning point for Trevi Therapeutics Inc.Insider Selling & Weekly Top Gainers Trade List - newser.com
Technical signs of recovery in Trevi Therapeutics Inc.Trade Risk Report & Fast Exit/Entry Strategy Plans - newser.com
Is Trevi Therapeutics Inc. stock a buy for dividend growthTrade Performance Summary & Safe Entry Zone Identification - newser.com
Leerink Partners raises Trevi Therapeutics stock price target to $16 on Haduvio outlook - Investing.com Canada
Should I hold or sell Trevi Therapeutics Inc. stock in 2025CEO Change & Consistent Profit Trade Alerts - newser.com
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk (NASDAQ:TRVI) - Seeking Alpha
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Strong Earnings - MarketBeat
Momentum divergence signals in Trevi Therapeutics Inc. chartMarket Sentiment Summary & Reliable Entry Point Alerts - newser.com
What MACD signals say about Trevi Therapeutics Inc.July 2025 WrapUp & Entry Point Strategy Guides - newser.com
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension - Yahoo Finance
How Trevi Therapeutics’ (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations - Yahoo Finance
Oppenheimer Maintains Trevi Therapeutics (TRVI) Outperform Recommendation - Nasdaq
Trevi Therapeutics (NASDAQ:TRVI) Posts Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Ca - GuruFocus
Cantor Fitzgerald reiterates Overweight rating on Trevi Therapeutics stock By Investing.com - Investing.com Canada
Oppenheimer Raises Price Target for Trevi Therapeutics (TRVI) to $24 | TRVI Stock News - GuruFocus
Historical volatility pattern of Trevi Therapeutics Inc. visualizedMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Leerink Partners Begins Coverage on Trevi Therapeutics (NASDAQ:TRVI) - MarketBeat
TRVI: Morgan Stanley Raises Price Target Amid Continued Overweig - GuruFocus
Oppenheimer Adjusts Trevi Therapeutics PT to $24 From $23, Maintains Outperform Rating - MarketScreener
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2025 Earnings Call Transcript - Insider Monkey
Trevi Therapeutics (TRVI) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
Oppenheimer raises Trevi Therapeutics stock price target on chronic cough program expansion - Investing.com Canada
Clear Street raises Trevi Therapeutics stock price target to $21 on clinical progress - Investing.com Canada
Clear Street Maintains Trevi Therapeutics (TRVI) Buy Recommendation - Nasdaq
TRVI: Analyst Maintains 'Buy' Rating and Raises Price Target | T - GuruFocus
Why retail investors pile into Trevi Therapeutics Inc. stockJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - Fundação Cultural do Pará
Trevi Therapeutics Inc (TRVI) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Decoding Trevi Therapeutics Inc (TRVI): A Strategic SWOT Insight - GuruFocus
Trevi Therapeutics Inc (TRVI) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Trevi Therapeutics Inc (TRVI) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Trevi Therapeutics Reports Q3 2025 Financials and Updates - TipRanks
Trevi Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Can Trevi Therapeutics Inc. stock reach $100 price target2025 Technical Overview & Accurate Entry and Exit Point Alerts - newser.com
Trevi Therapeutics Trims Losses And Banks On Future Trials - Finimize
Earnings call transcript: Trevi Therapeutics reports Q3 2025 results with EPS surprise - Investing.com Australia
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):